With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.452339-73-0,(R)-5-(2,2-Dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2-one,as a common compound, the synthetic route is as follows.
(5R)-5-(2, 2-Dimethyl-4H-1, 3-benzodioxin-6-yl)-1, 3-oxazolidin-2-one (651 mg) in DMF (15mL) was treated with sodium hydride (84mg) under nitrogen and stirred for 1 h. A solution of 2- [4- (2-bromoethyl) phenoxy] ethyl acetate (500mg) in DMF (5mL) was added and the reaction mixture was stirred for a further 2 h. This was then concentrated in vacuo and the residue was taken up in EtOAc, washed with water, brine and dried (MgS04). The solution was concentrated in vacuo and the residue was purified by chromatography (Biotage, 90g) eluting with cyclohexane-EtOAc (2: 1) to give the title compound (355mg). LCMS RT=3. 26min.
452339-73-0, As the paragraph descriping shows that 452339-73-0 is playing an increasingly important role.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2003/91204; (2003); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem